The abstract is read at the publisher; the summary is JClub's.
HB0025 plus chemotherapy produced confirmed objective response rates of 36.4% and 57.1% in previously untreated driver variant-negative nonsquamous advanced NSCLC, with manageable toxicity.
- Why it matters: Advanced driver variant-negative NSCLC needs effective first-line options that combine immune checkpoint and VEGF pathway targeting, while maintaining acceptable safety.
- What they did: In an open-label, multicenter phase 2 nonrandomized trial in China, patients received 10-mg/kg or 20-mg/kg HB0025 every 3 weeks with pemetrexed/carboplatin, then HB0025 maintenance, and investigators assessed ORR.
- The result: In the nonsquamous cohort (n=85), median progression-free survival was 12.52 months (95% CI, 10.15-16.56), grade 3+ treatment-related adverse events occurred in 65.9%, and immune-related adverse events occurred in 23.5%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.